Y Intercept Hong Kong Ltd Sells 160,596 Shares of AngioDynamics, Inc. $ANGO

Y Intercept Hong Kong Ltd decreased its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 71.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 63,918 shares of the medical instruments supplier’s stock after selling 160,596 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in AngioDynamics were worth $714,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of ANGO. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in AngioDynamics by 13.5% in the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,747 shares of the medical instruments supplier’s stock worth $166,000 after purchasing an additional 1,989 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in shares of AngioDynamics in the 3rd quarter worth about $25,000. Rhumbline Advisers increased its holdings in shares of AngioDynamics by 4.3% in the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock worth $608,000 after buying an additional 2,510 shares during the last quarter. Invesco Ltd. raised its position in shares of AngioDynamics by 2.2% during the 2nd quarter. Invesco Ltd. now owns 122,596 shares of the medical instruments supplier’s stock valued at $1,216,000 after buying an additional 2,667 shares in the last quarter. Finally, State of Wyoming bought a new position in shares of AngioDynamics in the 2nd quarter valued at about $31,000. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Stock Up 0.6%

ANGO opened at $10.42 on Tuesday. The business has a fifty day moving average of $12.02 and a 200 day moving average of $11.12. The stock has a market cap of $429.51 million, a P/E ratio of -15.55 and a beta of 0.52. AngioDynamics, Inc. has a 52-week low of $8.27 and a 52-week high of $13.99.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, January 6th. The medical instruments supplier reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.05). The business had revenue of $79.43 million for the quarter, compared to the consensus estimate of $76.43 million. AngioDynamics had a negative return on equity of 2.28% and a negative net margin of 9.02%.The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.04) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Equities analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Zacks Research raised AngioDynamics from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 9th. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, AngioDynamics currently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.